AVITA Medical, Inc. (ASX: AVH)

Market Cap	367.93M
Revenue (ttm)	86.60M
Net Income (ttm)	-82.67M
Shares Out	n/a
EPS (ttm)	-3.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	160,284
Average Volume	581,293
Open	2.840
Previous Close	2.840
Day's Range	2.790 - 2.840
52-Week Range	2.340 - 5.620
Beta	1.54
RSI	25.85
Earnings Date	Feb 13, 2025

About AVITA Medical

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2020
• Employees: 207
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AVH

Financial Performance

In 2023, AVITA Medical's revenue was $50.14 million, an increase of 45.68% compared to the previous year's $34.42 million. Losses were -$35.38 million, 32.7% more than in 2022.

Financial numbers in USD